Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy

In the published article, there was an error in the formula in the manuscript.

A correction has been made to Materials and Methods, Image analysis, Paragraph 2. This sentence previously stated:

“The percentages of post-treatment changes in metabolic parameters were calculated as follows:

$$\Delta \text{SUVmax}(\%)=\frac{\text{SUVmax of pre-treatment}-\text{SUVmax of post-treatment}}{\text{SUVmax of pretreatment }}\times 100\%$$

$$\text{ΔTLR}(\%)=\frac{\text{TLR of pre-treatment}-\text{TLR of post-treatment}}{\text{TLR of pre-treatment }}\times 100\%$$

$$\text{ΔPLR}(\%)=\frac{\text{PLR of pre-treatment}-\text{PLR of post-treatment}}{\text{PLR of pre-treatment }}\times 100\%”$$

The corrected sentence appears below:

“The percentages of post-treatment changes in metabolic parameters were calculated as follows:

$$\Delta \text{SUVmax}(\%)=\frac{\text{SUVmax of post-treatment}-\text{SUVmax of pre-treatment }}{\text{SUV of pre-treatment }}\times 100\%$$

$$\text{ΔTLR}(\%)=\frac{\text{TLR of post-treatment}-\text{TLR of pre-treatment}}{\text{TLR of pre-treatment }}\times 100\%$$

$$\text{ΔPLR}(\%)=\frac{\text{PLR of post-treatment}-\text{PLR of pre-treatment}}{\text{PLR of pre-treatment }}\times 100\%”$$

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.